ANTIVIRAL METHOD

Abstract

This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof.

Description

Claims

1. A method of inactivating non-enveloped virus particles, the method comprising: contacting non-enveloped virus particles with a virucidally-enhanced alcoholic composition comprising a C1-6 alcohol, and an efficacy-enhancing amount of one or more enhancers selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof, with the proviso that when the alcoholic composition comprises a proton donor, the composition further comprises a synergistic amount of a cationic oligomer or polymer.

2. The method of claim 1, wherein said method is operative to inactivate enveloped viruses and wherein said method further comprises: contacting enveloped virus with said composition.

3. The method of claim 1, wherein said method is operative to kill microbes including gram positive bacteria, gram negative bacteria, fungi, parasites, and wherein said method further comprises: contacting microbes with said composition.

4. The method of claim 1, wherein said composition comprises at least about 50 percent by weight of a C1-6 alcohol, based upon the total weight of the alcoholic composition.

5. The method of claim 1, wherein said composition comprises from about 0.02 to about 20 percent by weight of a cationic oligomer or polymer, based upon the total weight of the alcoholic composition.

6. The method of claim 5, wherein said cationic oligomer or polymer comprises a cationic polysaccharide, cationic copolymer of saccharide and a synthetic cationic monomer, cationic polyalkylene imines, cationic ethoxy polyalkylene imines, cationic poly[N-[3-(dialkylammonio)alkyl] N′[3-(alkyleneoxyalkylene dialkylammonio)alkyl]urea dichloride], vinyl caprolactam/VP/dialkylaminoalkyl alkylate copolymers, polyquaternium polymers or mixtures thereof.

7. The method of claim 6, wherein said cationic oligomer or polymer includes polyquaternium-2, polyquaternium-4, polyquaternium-5, polyquatemium-6, polyquatemium-7, polyquaternium-10, polyquaternium-11, polyquaternium-16, polyquaternium-22, polyquatemium-24, polyquaternium-28, polyquaternium-32, polyquaternium-37, polyquaternium-39, polyquaternium-42, polyquaternium-43, polyquaternium-44, polyquaternium-46, polyquaternium-47, polyquatemium-51, polyquaternium-53, polyquaternium-55, polyquaternium-57, polyquaternium-58, polyquaternium-59, polyquaternium-60, polyquaternium-63, polyquaternium-64, polyquaternium-65, polyquaternium-68, or mixtures thereof.

8. The method of claim 5, wherein said cationic oligomer or polymer is characterized by a charge density of at least about 0.1 meq/g.

9. The method of claim 1, wherein said composition comprises a C1-6 alcohol, a cationic oligomer or polymer, and a proton donor.

10. The method of claim 9, wherein said composition comprises from about 0.015 to about 1 percent by weight of a proton donor, based upon the total weight of the alcoholic composition.

11. The method of claim 9, wherein said proton donor comprises hydrochloric acid, nitric acid, phosphoric acid, phosphonic acid, boric acid, sulfuric acid, adipic acid, benzene 1,3,5 tricarboxylic acid, chlorosuccinic acid, choline chloride, cis-aconitic acid, citramalic acid, citric acid, cyclobutane 1,1,3,3 tetracarboxylic acid, cyclohexane 1,2,4,5 tetracarboxylic acid, cyclopentane 1,2,3,4 tetracarboxylic acid, diglycolic acid, fumaric acid, glutamic acid, glutaric acid, glyoxylic acid, isocitric acid, ketomalonic acid, lactic acid, maleic acid, malic acid, malonic acid, nitrilotriacetic acid, oxalacetic acid, oxalic acid, phytic acid, p-toluenesulfonic acid, salicylic acid, succinic acid, tartaric acid, tartronic acid, tetrahydrofuran 2,3,4,5 tetracarboxylic acid, tricarballylic acid, versene acids, 3-hydroxyglutaric acid, 2-hydroxypropane 1,3 dicarboxylic acid, glyceric acid, furan 2,5 dicarboxylic acid, 3,4-dihydroxyfuran-2,5 dicarboxylic acid, 3,4-dihydroxytetrahydrofuran-2,5-dicarboxylic acid, 2-oxo-glutaric acid, dl-glyceric acid, 2,5 furandicarboxylic acid, or mixtures thereof.

12. The method of claim 1, wherein said composition comprises a C1-6 alcohol, a cationic oligomer or polymer, and an effective amount of a zinc or copper ion.

13. The method of claim 12, wherein said composition comprises from about 0.01 to about 1 percent by weight of a zinc or copper compound, based upon the total weight of the alcoholic composition, and less than about 0.05 percent by weight acid.

14. The method of claim 13, wherein said zinc or copper compound includes zinc gluconate or copper gluconate.

15. The method of claim 1, wherein said composition comprises a C1-6 alcohol, a cationic oligomer or polymer, and a chaotropic agent.

16. The method of claim 15, wherein said composition comprises from about 0.25 to about 20 percent by weight chaotropic agent, based upon the total weight of the alcoholic composition.

17. The method of claim 15, wherein said chaotropic agent comprises urea, thiourea, guanidine HCl, guanidine thiocyanate, aminoguanidine HCl, aminoguanidine bicarbonate, guanidine carbonate, guanidine phosphate, or mixtures thereof.

18. The method of claim 1, wherein said method exhibits an increased log reduction against said non-enveloped virus particles, when compared to the log reduction of a composition comprising the same amount of said C1-6 alcohol, and less than an efficacy-enhancing amount of said enhancer.

19. The method of claim 1, wherein said method exhibits at least a 1 log reduction against said non-enveloped virus particles in 60 seconds or less.

20. The method of claim 1, wherein said method exhibits at least a 2 log reduction against said non-enveloped virus particles in 60 seconds or less.

21. The method of claim 1, wherein said method exhibits at least a 3 log reduction against said non-enveloped virus particles in 60 seconds or less.

22. The method of claim 1, wherein said non-enveloped virus particles are selected from members of the families Picornaviridae, Reoviridae, Caliciviridae, Adenoviridae and Parvoviridae.

23. The method of claim 1, wherein said non-enveloped virus particles are selected from adenovirus, feline calicivirus, norovirus, papillomavirus, poliovirus, rhinovirus, hepatitis A virus, parvovirus, and rotavirus.

24. A method of producing a topical virucidal effect on mammalian skin against non-enveloped virus by applying a virucidally-enhanced alcoholic composition comprising a C1-6 alcohol, and an efficacy-enhancing amount of one or more enhancers selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof, with the proviso that when the alcoholic composition comprises a proton donor, the composition further comprises a synergistic amount of a cationic oligomer or polymer.

25. The method of claim 24, wherein said method further produces a topical virucidal effect against enveloped viruses.

26. The method of claim 24, wherein said method further produces a topical virucidal effect against microbes including gram positive bacteria, gram negative bacteria, fungi, parasites.

27. The method of claim 24, wherein said composition comprises at least about 50 percent by weight of a C1-6 alcohol, based upon the total weight of the alcoholic composition.

28. The method of claim 24, wherein said composition comprises from about 0.02 to about 20 percent by weight of a cationic oligomer or polymer, based upon the total weight of the alcoholic composition.

29. The method of claim 28, wherein said cationic oligomer or polymer comprises a cationic polysaccharide, cationic copolymer of saccharide and a synthetic cationic monomer, cationic polyalkylene imines, cationic ethoxy polyalkylene imines, cationic poly[N-[3-(dialkylammonio)alkyl] N′[3-(alkyleneoxyalkylene dialkylammonio)alkyl]urea dichloride], vinyl caprolactam/VP/dialkylaminoalkyl alkylate copolymers, polyquaternium polymers or mixtures thereof.

30. The method of claim 28, wherein said cationic oligomer or polymer includes polyquaternium-2, polyquaternium-4, polyquatemium-5, polyquatemium-6, polyquaternium-7, polyquaternium-10, polyquaternium-11, polyquaternium-16, polyquaternium-22, polyquaternium-24, polyquaternium-28, polyquaternium-32, polyquaternium-37, polyquaternium-39, polyquaternium-42, polyquaternium-43, polyquaternium-44, polyquaternium-46, polyquaternium-47, polyquaternium-51, polyquaternium-53, polyquaternium-55, polyquaternium-57, polyquaternium-58, polyquaternium-59, polyquaternium-60, polyquaternium-63, polyquaternium-64, polyquaternium-65, polyquaternium-68, or mixtures thereof.

31. The method of claim 28, wherein said cationic oligomer or polymer is characterized by a charge density of at least about 0.1 meq/g.

32. The method of claim 24, wherein said composition comprises a C1-6 alcohol, a cationic oligomer or polymer, and a proton donor.

33. The method of claim 32, wherein said composition comprises from about 0.015 to about 1 percent by weight of a proton donor, based upon the total weight of the alcoholic composition.

34. The method of claim 24, wherein said proton donor comprises hydrochloric acid, nitric acid, phosphoric acid, phosphonic acid, boric acid, sulfuric acid, adipic acid, benzene 1,3,5 tricarboxylic acid, chlorosuccinic acid, choline chloride, cis-aconitic acid, citramalic acid, citric acid, cyclobutane 1,1,3,3 tetracarboxylic acid, cyclohexane 1,2,4,5 tetracarboxylic acid, cyclopentane 1,2,3,4 tetracarboxylic acid, diglycolic acid, fumaric acid, glutamic acid, glutaric acid, glyoxylic acid, isocitric acid, ketomalonic acid, lactic acid, maleic acid, malic acid, malonic acid, nitrilotriacetic acid, oxalacetic acid, oxalic acid, phytic acid, p-toluenesulfonic acid, salicylic acid, succinic acid, tartaric acid, tartronic acid, tetrahydrofuran 2,3,4,5 tetracarboxylic acid, tricarballylic acid, versene acids, 3-hydroxyglutaric acid, 2-hydroxypropane 1,3 dicarboxylic acid, glyceric acid, furan 2,5 dicarboxylic acid, 3,4-dihydroxyfuran-2,5 dicarboxylic acid, 3,4-dihydroxytetrahydrofuran-2,5-dicarboxylic acid, 2-oxo-glutaric acid, dl-glyceric acid, 2,5 furandicarboxylic acid, or mixtures thereof.

35. The method of claim 24, wherein said composition comprises a C1-6 alcohol, a cationic oligomer or polymer, and a synergistic amount of a zinc or copper compound.

36. The method of claim 35, wherein said zinc or copper compound includes zinc gluconate or copper gluconate.

37. The method of claim 35, wherein said composition comprises from at least about 10 ppm of a zinc or copper ion, based upon the total weight of the alcoholic composition, and less than about 0.05 wt. % acid.

38. The method of claim 24, wherein said composition comprises C1-6 alcohol, a cationic oligomer or polymer, and a chaotropic agent.

39. The method of claim 38, wherein said composition comprises from about 0.25 to about 20 percent by weight chaotropic agent, based upon the total weight of the alcoholic composition.

40. The method of claim 38, wherein said chaotropic agent comprises urea, thiourea, guanidine HCl, guanidine thiocyanate, aminoguanidine HCl, aminoguanidine bicarbonate, guanidine carbonate, guanidine phosphate, or mixtures thereof.

41. The method of claim 24, wherein said method exhibits an increased log reduction against said non-enveloped virus particles, when compared to the log reduction of a composition comprising the same amount of said C1-6 alcohol, and less than an efficacy-enhancing amount of said enhancer.

42. The method of claim 24, wherein said method exhibits at least a 1 log reduction against said non-enveloped virus particles in 60 seconds or less.

43. The method of claim 24, wherein said method exhibits at least a 2 log reduction against said non-enveloped virus particles in 60 seconds or less.

44. The method of claim 24, wherein said method exhibits at least a 3 log reduction against said non-enveloped virus particles in 60 seconds or less.

45. The method of claim 24, wherein said non-enveloped virus particles are selected from members of the families Picornaviridae, Reoviridae, Caliciviridae, Adenoviridae and Parvoviridae.

46. The method of claim 24, wherein said non-enveloped virus particles are selected from adenovirus, feline calicivirus, norovirus, papillomavirus, poliovirus, rhinovirus, hepatitis A virus, parvovirus, and rotavirus.

47. A method of enhancing the efficacy of a C1-6 alcohol against non-enveloped virus in a topical application to a surface, the method comprising: combining said C1-6 alcohol with an efficacy-enhancing amount of an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof, to form an antiviral composition, with the proviso that where the antiviral composition comprises a proton donor, the composition further comprises a synergistic amount of a cationic oligomer or polymer.

48. The method of claim 47, wherein said method further produces a topical virucidal effect against enveloped viruses.

49. The method of claim 47, wherein said method further produces a topical virucidal effect against microbes including gram positive bacteria, gram negative bacteria, fungi, parasites.

50. The method of claim 47, wherein said composition comprises at least about 50 percent by weight of a C1-6 alcohol, based upon the total weight of the antiviral composition.

51. The method of claim 47, wherein said composition comprises from about 0.02 to about 20 percent by weight of a cationic oligomer or polymer, based upon the total weight of the antiviral composition.

52. The method of claim 51, wherein said cationic oligomer or polymer comprises a cationic polysaccharide, cationic copolymer of saccharide and a synthetic cationic monomer, cationic polyalkylene imines, cationic ethoxy polyalkylene imines, cationic poly[N-[3-(dialkylammonio)alkyl] N′[3-(alkyleneoxyalkylene dialkylammonio)alkyl]urea dichloride], vinyl caprolactam/VP/dialkylaminoalkyl alkylate copolymers, polyquaternium polymers or mixtures thereof.

53. The method of claim 51, wherein said cationic oligomer or polymer includes polyquaternium-2, polyquaternium-4, polyquaternium-5, polyquatemium-6, polyquaternium-7, polyquaternium-10, polyquaternium-11, polyquaternium-16, polyquaternium-22, polyquaternium-24, polyquaternium-28, polyquatemium-32, polyquaternium-37, polyquaternium-39, polyquaternium-42, polyquaternium-43, polyquaternium-44, polyquaternium-46, polyquaternium-47, polyquaternium-51, polyquaternium-53, polyquatemium-55, polyquaternium-57, polyquaternium-58, polyquaternium-59, polyquaternium-60, polyquaternium-63, polyquaternium-64, polyquaternium-65, polyquaternium-68, or mixtures thereof.

54. The method of claim 51, wherein said cationic oligomer or polymer is characterized by a charge density of at least about 0.1 meq/g.

55. The method of claim 47, wherein said composition comprises a C1-6 alcohol, a cationic oligomer or polymer, and a proton donor.

56. The method of claim 55, wherein said composition comprises from about 0.015 to about 1 percent by weight of a proton donor, based upon the total weight of the alcoholic composition.

57. The method of claim 55, wherein said proton donor comprises hydrochloric acid, nitric acid, phosphoric acid, phosphonic acid, boric acid, sulfuric acid, adipic acid, benzene 1,3,5 tricarboxylic acid, chlorosuccinic acid, choline chloride, cis-aconitic acid, citramalic acid, citric acid, cyclobutane 1,1,3,3 tetracarboxylic acid, cyclohexane 1,2,4,5 tetracarboxylic acid, cyclopentane 1,2,3,4 tetracarboxylic acid, diglycolic acid, fumaric acid, glutamic acid, glutaric acid, glyoxylic acid, isocitric acid, ketomalonic acid, lactic acid, maleic acid, malic acid, malonic acid, nitrilotriacetic acid, oxalacetic acid, oxalic acid, phytic acid, p-toluenesulfonic acid, salicylic acid, succinic acid, tartaric acid, tartronic acid, tetrahydrofuran 2,3,4,5 tetracarboxylic acid, tricarballylic acid, versene acids, 3-hydroxyglutaric acid, 2-hydroxypropane 1,3 dicarboxylic acid, glyceric acid, furan 2,5 dicarboxylic acid, 3,4-dihydroxyfuran-2,5 dicarboxylic acid, 3,4-dihydroxytetrahydrofuran-2,5-dicarboxylic acid, 2-oxo-glutaric acid, dl-glyceric acid, 2,5 furandicarboxylic acid, or mixtures thereof.

58. The method of claim 47, wherein said composition comprises a C1-6 alcohol, a cationic oligomer or polymer, and a synergistic amount of a zinc or copper compound.

59. The method of claim 58, wherein said zinc or copper compound includes zinc gluconate or copper gluconate.

60. The method of claim 58, wherein said composition comprises at least about 10 ppm by weight of a zinc or copper ion, based upon the total weight of the alcoholic composition.

61. The method of claim 47, wherein said composition comprises C1-6 alcohol, a cationic oligomer or polymer, and a chaotropic agent.

62. The method of claim 47, wherein said composition comprises from about 0.25 to about 20 percent by weight chaotropic agent, based upon the total weight of the antiviral composition.

63. The method of claim 47, wherein said chaotropic agent comprises urea, thiourea, guanidine HCl, guanidine thiocyanate, aminoguanidine HCl, aminoguanidine bicarbonate, guanidine carbonate, guanidine phosphate, or mixtures thereof.

64. The method of claim 47, wherein said antiviral composition exhibits an increased efficacy against said non-enveloped virus, when compared to the efficacy of a composition comprising the same amount of said C1-6 alcohol, and less than an efficacy-enhancing amount of said enhancer.

65. The method of claim 47, wherein said method exhibits at least a 1 log reduction against said non-enveloped virus particles in 60 seconds or less.

66. The method of claim 47, wherein said method exhibits at least a 3 log reduction against said non-enveloped virus particles in 60 seconds or less.

67. The method of claim 47, wherein said surface includes a porous or non-porous surface.

68. The method of claim 47, wherein said non-enveloped virus particles are selected from members of the families Picornaviridae, Reoviridae, Caliciviridae, Adenoviridae and Parvoviridae.

69. The method of claim 47, wherein said non-enveloped virus particles are selected from adenovirus, feline calicivirus, norovirus, papillomavirus, poliovirus, rhinovirus, hepatitis A virus, parvovirus, and rotavirus.

70. A virucidally-enhanced alcoholic composition comprising: a C1-6 alcohol; and an efficacy-enhancing amount of an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof, with the proviso that where the alcoholic composition comprises a proton donor, the composition further comprises a synergistic amount of a cationic oligomer or polymer, wherein said virucidal composition exhibits an efficacy against non-enveloped viruses that is higher than the efficacy of the same composition but not comprising said enhancer.

71. The composition of claim 70, wherein said virucidal composition exhibits an efficacy against non-enveloped viruses that is at least about 0.5 log reduction higher than the efficacy of the same composition but not comprising said enhancer.

72. The composition of claim 70, wherein said virucidal composition exhibits an efficacy against non-enveloped viruses that is at least about 1 log reduction higher than the efficacy of the same composition but not comprising said enhancer.

73. The composition of claim 70, wherein said enhancer comprises a proton donor selected from the group consisting of hydrochloric acid, nitric acid, phosphoric acid, phosphonic acid, boric acid, sulfuric acid, adipic acid, benzene 1,3,5 tricarboxylic acid, chlorosuccinic acid, choline chloride, cis-aconitic acid, citramalic acid, citric acid, cyclobutane 1,1,3,3 tetracarboxylic acid, cyclohexane 1,2,4,5 tetracarboxylic acid, cyclopentane 1,2,3,4 tetracarboxylic acid, diglycolic acid, fumaric acid, glutamic acid, glutaric acid, glyoxylic acid, isocitric acid, ketomalonic acid, lactic acid, maleic acid, malic acid, malonic acid, nitrilotriacetic acid, oxalacetic acid, oxalic acid, phytic acid, p-toluenesulfonic acid, salicylic acid, succinic acid, tartaric acid, tartronic acid, tetrahydrofuran 2,3,4,5 tetracarboxylic acid, tricarballylic acid, versene acids, 3-hydroxyglutaric acid, 2-hydroxypropane 1,3 dicarboxylic acid, glyceric acid, furan 2,5 dicarboxylic acid, 3,4-dihydroxyfuran-2,5 dicarboxylic acid, 3,4-dihydroxytetrahydrofuran-2,5-dicarboxylic acid, 2-oxo-glutaric acid, dl-glyceric acid, 2,5 furandicarboxylic acid, and mixtures thereof.

74. The composition of claim 70, wherein said enhancer comprises a chaotropic agent selected from the group consisting of urea, thiourea, guanidine HCl, guanidine thiocyanate, aminoguanidine HCl, and mixtures thereof.

75. The composition of claim 70, wherein said enhancer comprises a cationic oligomer or polymer selected from the group consisting of cationic polysaccharides, cationic copolymers of saccharide and a synthetic cationic monomer, cationic polyalkylene imines, cationic ethoxy polyalkylene imines, cationic poly[N-[3-(dialkylammonio)alkyl] N′[3-(alkyleneoxyalkylene dialkylammonio)alkyl]urea dichloride], vinyl caprolactam/VP/dialkylaminoalkyl alkylate copolymers, polyquaternium polymers and mixtures thereof.

76. The composition of claim 75, wherein said cationic oligomer or polymer comprises a polyquaternium selected from the group consisting of polyquaternium-2, polyquaternium-4, polyquaternium-5, polyquatemium-6, polyquaternium-7, polyquaternium-10, polyquatemium-11, polyquaternium-16, polyquaternium-22, polyquaternium-24, polyquaternium-28, polyquaternium-32, polyquaternium-37, polyquaternium-39, polyquaternium-42, polyquaternium-43, polyquaternium-44, polyquaternium-46, polyquaternium-47, polyquaternium-51, polyquaternium-53, polyquaternium-55, polyquaternium-57, polyquaternium-58, polyquatemium-59, polyquaternium-60, polyquaternium-63, polyquaternium-64, polyquaternium-65, polyquaternium-68, and mixtures thereof.

77. The composition of claim 76, wherein said composition comprises from about 0.2 to about 2 percent by weight of a cationic oligomer or polymer selected from the group consisting of polyquaternium-2, polyquaternium-16, polyquaternium-22, polyquatemium-37, and mixtures thereof, based upon the total weight of the composition.

78. The composition of claim 77, wherein said composition comprises polyquaternium-37.

79. The composition of claim 78, wherein said composition comprises from about 0.05 to about 1 percent by weight of citric acid.

80. The composition of claim 78, wherein said composition comprises from about 0.25 to about 10 percent by weight of urea.

81. The composition of claim 78, wherein said composition comprises from about 0.01 to about 1 percent by weight of copper gluconate.

82. The composition of claim 77, wherein said composition comprises polyquaternium-2.

83. The composition of claim 82, wherein said composition comprises from about 0.05 to about 1 percent by weight of citric acid.

84. The composition of claim 82, wherein said composition comprises from about 0.25 to about 10 percent by weight of urea.

85. The composition of claim 77, wherein said composition comprises polyquaternium-16.

86. The composition of claim 85, wherein said composition comprises from about 0.05 to about 1 percent by weight of citric acid.

87. The composition of claim 85, wherein said composition comprises from about 0.25 to about 10 percent by weight of urea.

88. The composition of claim 77, wherein said composition comprises polyquaternium-22.

89. The composition of claim 85, wherein said composition comprises from about 0.05 to about 1 percent by weight of citric acid.

90. The composition of claim 85, wherein said composition comprises from about 0.25 to about 10 percent by weight of urea.